Showing 4 posts of 4 posts found.


Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure

April 26, 2019
Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma

Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …

EMA rejects Lilly’s Lartruvo in soft tissue cancer following trial failure

January 24, 2019
Sales and Marketing Cancer, EMA, Eli Lilly, Lartruvo, pharma

Eli Lilly has been dealt a blow as the European Medicines Agency announced its recommendation for soft tissue cancer patients …

MSD and Lilly announce immuno-oncology collaboration

January 11, 2017
Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly

MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …


EU recommendation for Lilly’s soft tissue cancer drug

September 19, 2016
Sales and Marketing CHMP, EMA, Eli Lilly, Lartruvo, soft tissue sarcoma

The Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Lartruvo (olaratumab) for treatment of adults with …

Latest content